PM-SARS2-RBDMUT02-1

PepMix™ SARS-CoV-2 (S-RBD B.1.351 / Beta)

US$551.20

In stock

Description

About PepMix™ SARS-CoV-2 (S-RBD B.1.351 / Beta)

Peptide scan through Spike glycoprotein - Receptor binding domain of SARS-CoV-2 Lineage B.1.351, South Africa covering the following mutations: K0417N, E0484K, N0501Y) for T cell assays (e.g. ELISPOT).

Pool of 53 peptides derived from a peptide scan (15mers with 11 aa overlap) through Receptor Binding Domain of Spike Glycoprotein - contains mutations K0417N, E0484K, N0501Y of SARS-CoV-2 (Severe Acute Respiratory Syndrome-Related Coronavirus 2) - (Lineage B.1.351, Gamma Variant).

PepMix™ SARS-CoV-2 (S-RBD B.1.351 / Beta) - Specifications

Amount: 25 µg (approx. 15 nmol) / peptide (for stimulation of up to 2,5 x 10⁸ cells)
Purity: Research Plus Grade: each peptide is guaranteed to be main product (HPLC/MS) - (equivalent to an average purity of 70%)
Delivery Format: Freeze-dried in glass vial
Application(s): T-cell Immunity
Condition(s)/Topic(s): Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
Standard Delivery Time: 2-5 days

Visit our webpage for more information on SARS-CoV-2, its mutations & variants and our corresponding products.

Are you interested in your own custom PepMix? Choose your sequence, amount, purity and pool format. We will assist you along the way. Custom PepMix Peptide Pools.

PepMix™ Peptide Pools
Protein-spanning mixtures of overlapping peptides (PepMix™) are extremely efficient for
- Antigen-specific T cell stimulation in T cell assays (e.g. in ELISpot, ICS, cell-mediated cytotoxicity or proliferation assays)
- In-vitro T cell expansion
- Dendritic cell pulsing
- Immune monitoring
- Cellular immune response profiling
- T cell epitope identification
- Standardization of T cell assays

Benefits of PepMix™
- Each peptide quality controlled and guaranteed for identity and purity
- CoA and HPLC-MS data available
- High batch-to-batch consistency
- No false positive T cell responses by contaminating deletion peptides
- No toxic inhibition of T cell responses due to stringent purification of each peptide
- Minimization of endotoxin contamination due to low bioburden process
- ADCF policy in place
- HLA independent stimulation (with antigen spanning peptide pools)

References

References for PepMix™ SARS-CoV-2 (S-RBD B.1.351 / Beta)

References
Read References with
PepMix™ Peptide Pools for Infectious Diseases
COVID-19 related PepMixes™
PepMix™ Control Pools

Application Notes
Cross-reactive T cells enhance immune responses in SARS-CoV-2 infection and vaccination
Loyal et al (2021) Full text
Peptide Tools to Support the Fight against COVID-19
Alem et al (2020) Full text
CEFX/EFX Ultra SuperStim Pools: Superior positive controls for T-cell assays with broad MHC-allele and antigen coverage
Eckey et al. (2017) Full text
Developing Multi-HIV Antigen Specific T-Cells as a Component of a Cure Strategy
Lam et al. (2015) Full text
Peptide-stimulated Expansion of Virus-specific T cells For Preventative Treatment After Allogeneic Stem Cell Transplantation
Gary et al. (2015) Full text
PepMix™ Peptide Pools for Clinical Applications: T Cell Therapy for Viral Infections after Hematopoietic Stem Cell Transplant
Keirnan et al. (2012) Full text
Cytomegalovirus Protein Spanning PepMix™ Peptide Pools to Discover Changes in T-Cell Immunity in the Aging Population
Kern (2012) Full text

Testimonials
"To establish a novel role for myeloid derived suppressor cells (Pallett et al, Nat. Med. 2015) in chronic viral infection, we utilised the PepMix CEF Pool (extended) as well as a custom synthesized PepMix spanning the core region of HBV genotype D . Whereas, the CEF peptide pool consists of 32 peptides, each corresponding to a defined HLA class I-restricted T-cell epitope from Cytomegalo, Epstein-Barr, and Influenza virus, the latter custom PepMix included 15meric peptides overlapping by 10 amino acids. Specifically this composition enabled us to monitor both the antiviral CD8+ and CD4+ T cell responses in chronic HBV infection and the non-antigen specific T cells that are known to mediate immunopathology in the liver. Our entire experience with JPT, from ordering/delivery to use in the lab was excellent. Not only were the reagents able to perform reliably and consistently in vitro from batch to batch, the customer and technical support provided was continually available and efficient when needed. JPT will remain our go-to company for purchasing peptides."
Dr. Laura J Pallett, Infection and Immunity, University College London, UK

Documentation

Documentation for PepMix™ SARS-CoV-2 (S-RBD B.1.351 / Beta)

Properties

Properties of PepMix™ SARS-CoV-2 (S-RBD B.1.351 / Beta)

Amount:	25 µg (approx. 15 nmol) / peptide (for stimulation of up to 2,5 x 108 cells)
Application:	T-cell immunity
Category:	PepMix Peptide Pools, PepMix Peptide Pools Infections
Condition / Topic:	Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS)
Layout:	Freeze-dried in glass vial
Organism:	SARS-CoV-2 (Severe Acute Respiratory Syndrome-related coronavirus 2)
Protein Name:	Receptor Binding Domain of Spike Glycoprotein
Quantification:	No

Further Information to PepMix™ SARS-CoV-2 (S-RBD B.1.351 / Beta)

Information	Values
Sequence:	RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF
Specifications:	Peptide scan (15mers with 11 aa overlap)